These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 37428418)
21. Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy. De Angelis C; Nagi C; Hoyt CC; Liu L; Roman K; Wang C; Zheng Y; Veeraraghavan J; Sethunath V; Nuciforo P; Wang T; Tsimelzon A; Mao S; Hilsenbeck SG; Trivedi MV; Cataldo ML; Pavlick A; Wolff AC; Weigelt B; Reis-Filho JS; Prat A; Gutierrez C; Osborne CK; Rimawi MF; Schiff R Clin Cancer Res; 2020 Feb; 26(3):738-745. PubMed ID: 31653641 [TBL] [Abstract][Full Text] [Related]
22. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy. Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323 [TBL] [Abstract][Full Text] [Related]
23. Neutrophil-lymphocyte ratio reflects tumour-infiltrating lymphocytes and tumour-associated macrophages and independently predicts poor outcome in breast cancers with neoadjuvant chemotherapy. Li JJX; Ni SYB; Tsang JYS; Chan WY; Hung RKW; Lui JWH; Ng SWY; Shum LK; Tang YF; Tse GM Histopathology; 2024 Apr; 84(5):810-821. PubMed ID: 38192219 [TBL] [Abstract][Full Text] [Related]
24. The presence of tumour-infiltrating lymphocytes (TILs) and the ratios between different subsets serve as prognostic factors in advanced hypopharyngeal squamous cell carcinoma. Wang J; Tian S; Sun J; Zhang J; Lin L; Hu C BMC Cancer; 2020 Aug; 20(1):731. PubMed ID: 32758195 [TBL] [Abstract][Full Text] [Related]
25. Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer. Takada K; Kashiwagi S; Goto W; Asano Y; Takahashi K; Takashima T; Tomita S; Ohsawa M; Hirakawa K; Ohira M J Transl Med; 2018 Apr; 16(1):86. PubMed ID: 29615076 [TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers. Fujimoto Y; Watanabe T; Hida AI; Higuchi T; Miyagawa Y; Ozawa H; Bun A; Fukui R; Sata A; Imamura M; Hirota S; Miyoshi Y Breast Cancer; 2019 Nov; 26(6):738-747. PubMed ID: 31098866 [TBL] [Abstract][Full Text] [Related]
27. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer. Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145 [TBL] [Abstract][Full Text] [Related]
28. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. Luen SJ; Salgado R; Fox S; Savas P; Eng-Wong J; Clark E; Kiermaier A; Swain SM; Baselga J; Michiels S; Loi S Lancet Oncol; 2017 Jan; 18(1):52-62. PubMed ID: 27964843 [TBL] [Abstract][Full Text] [Related]
29. The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer. Li J; Wang J; Chen R; Bai Y; Lu X Oncotarget; 2017 Feb; 8(9):15621-15631. PubMed ID: 28152503 [TBL] [Abstract][Full Text] [Related]
30. Tumor-associated lymphocytes and macrophages are related to stromal elastosis and vascular invasion in breast cancer. Chen Y; Klingen TA; Aas H; Wik E; Akslen LA J Pathol Clin Res; 2021 Sep; 7(5):517-527. PubMed ID: 34076969 [TBL] [Abstract][Full Text] [Related]
31. Spatial Distribution and Densities of CD103+ and FoxP3+ Tumor Infiltrating Lymphocytes by Digital Analysis for Outcome Prediction in Breast Cancer. Chan R; Aphivatanasiri C; Poon IK; Tsang JY; Ni Y; Lacambra M; Li J; Lee C; Tse GM Oncologist; 2024 Mar; 29(3):e299-e308. PubMed ID: 37491001 [TBL] [Abstract][Full Text] [Related]
32. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559 [TBL] [Abstract][Full Text] [Related]
33. Prognostic implications of tumor-infiltrating FoxP3+ regulatory T cells and CD8+ cytotoxic T cells in microsatellite-unstable gastric cancers. Kim KJ; Lee KS; Cho HJ; Kim YH; Yang HK; Kim WH; Kang GH Hum Pathol; 2014 Feb; 45(2):285-93. PubMed ID: 24331841 [TBL] [Abstract][Full Text] [Related]
34. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer. Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586 [TBL] [Abstract][Full Text] [Related]
35. Histopathological analysis of tumor microenvironment in adrenocortical carcinoma: Possible effects of in situ disorganized glucocorticoid production on tumor immunity. Ishikawa Y; Yamazaki Y; Tezuka Y; Omata K; Ono Y; Tokodai K; Fujishima F; Kawanabe S; Katabami T; Ikeya A; Yamashita M; Oki Y; Nanjo H; Satoh F; Ito A; Unno M; Kamei T; Sasano H; Suzuki T J Steroid Biochem Mol Biol; 2024 Apr; 238():106462. PubMed ID: 38232786 [TBL] [Abstract][Full Text] [Related]
36. Evaluation of the prognostic value of CD3, CD8, and FOXP3 mRNA expression in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapy. Tsiatas M; Kalogeras KT; Manousou K; Wirtz RM; Gogas H; Veltrup E; Zagouri F; Lazaridis G; Koutras A; Christodoulou C; Pentheroudakis G; Petraki C; Bafaloukos D; Pectasides D; Kosmidis P; Samantas E; Karanikiotis C; Papakostas P; Dimopoulos MA; Fountzilas G Cancer Med; 2018 Oct; 7(10):5066-5082. PubMed ID: 30240146 [TBL] [Abstract][Full Text] [Related]
37. Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study. Cimino-Mathews A; Ye X; Meeker A; Argani P; Emens LA Hum Pathol; 2013 Oct; 44(10):2055-63. PubMed ID: 23701942 [TBL] [Abstract][Full Text] [Related]
38. Prognostic and predictive role of tumour-associated macrophages in HER2 positive breast cancer. Honkanen TJ; Tikkanen A; Karihtala P; Mäkinen M; Väyrynen JP; Koivunen JP Sci Rep; 2019 Jul; 9(1):10961. PubMed ID: 31358801 [TBL] [Abstract][Full Text] [Related]
39. Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis. Gao G; Wang Z; Qu X; Zhang Z BMC Cancer; 2020 Mar; 20(1):179. PubMed ID: 32131780 [TBL] [Abstract][Full Text] [Related]
40. Tumor-infiltrating lymphocytes (TILs) in ER+/HER2- breast cancer. Criscitiello C; Vingiani A; Maisonneuve P; Viale G; Viale G; Curigliano G Breast Cancer Res Treat; 2020 Sep; 183(2):347-354. PubMed ID: 32621251 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]